Short-term efficacy of decitabine-based therapy in JMML: a retrospective study from a single center in China
Short-term efficacy of decitabine-based therapy in JMML: a retrospective study from a single center in China
复制标题
基于地西他滨治疗 JMML 的短期疗效：来自中国单中心的回顾性研究
DOI：
10.1007/s12185-022-03457-y
复制
发表时间：
2022-10
影响因子：
2.1
通讯作者：
Xiaofan Zhu
中科院分区：
文献类型：
--
作者：
Yuli Cai;Jingliao Zhang;Meihui Yi;Wenfeng Zhang;Xiaoming Liu;Xiaoyan Zhang;Yang Wan;Lixian Chang;Li Zhang;Xiaojuan Chen;Ye Guo;Yao Zou;Yumei Chen;Jun Li;Yingchi Zhang;Wenyu Yang;Xiaofan Zhu
幼年粒-单核细胞白血病(JMML)是一种侵袭性的儿童骨髓增生性疾病，初诊时由于病情较差，往往不能耐受造血干细胞移植(HSCT)。本研究旨在探讨地西他滨为主治疗对JMML患者HSCT前病情改善的近期效果。研究对象为10例JMML患者。所有患者在小剂量化疗后给予地西他滨治疗，间隔4周，然后过渡到HSCT。中位疗程3个周期，1周期总有效率(ORR)为70.0%，3周期总有效率(ORR)为71.4%。白细胞(WBC)和单核细胞计数在治疗后显著降低，脾体积也降低，尽管没有显著降低。12个月无进展生存率(PFS)为80.0 ± 12.6%。以地西他滨为主的治疗有利于减轻肿瘤负担，改善临床病情。
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myeloproliferative disease, and newly diagnosed patients frequently cannot tolerate hematopoietic stem cell transplantation (HSCT) at diagnosis due to their poor condition. This retrospective analysis aimed to explore the short-term effect of decitabine-dominant therapy on improving the condition of JMML patients before HSCT. The subjects were 10 JMML patients. All patients were treated with decitabine after low-dose chemotherapy with an interval of 4 weeks before bridging to HSCT. The median treatment course was 3 cycles, and the overall response rate (ORR) was 70.0% after one cycle and 71.4% after three cycles. White blood cell (WBC) and monocyte counts were significantly lower after treatment, and spleen volume was also lower, though not significantly lower. The 12 month progression-free survival rate (PFS) was 80.0 ± 12.6%. Decitabine-dominant therapy was beneficial for reducing tumor burden and improving clinical condition.
登录
查看更多内容
影响因子：
3.7
作者：
Sakaguchi H;Muramatsu H;Okuno Y;Makishima H;Xu Y;Furukawa-Hibi Y;Wang X;Narita A;Yoshida K;Shiraishi Y;Doisaki S;Yoshida N;Hama A;Takahashi Y;Yamada K;Miyano S;Ogawa S;Maciejewski JP;Kojima S
通讯作者：
Kojima S
影响因子：
3.2
作者：
Bergstraesser, Eva;Hasle, Henrik;Niemeyer, Charlotte M.
通讯作者：
Niemeyer, Charlotte M.
影响因子：
30.8
作者：
Stieglitz E;Taylor-Weiner AN;Chang TY;Gelston LC;Wang YD;Mazor T;Esquivel E;Yu A;Seepo S;Olsen S;Rosenberg M;Archambeault SL;Abusin G;Beckman K;Brown PA;Briones M;Carcamo B;Cooper T;Dahl GV;Emanuel PD;Fluchel MN;Goyal RK;Hayashi RJ;Hitzler J;Hugge C;Liu YL;Messinger YH;Mahoney DH Jr;Monteleone P;Nemecek ER;Roehrs PA;Schore RJ;Stine KC;Takemoto CM;Toretsky JA;Costello JF;Olshen AB;Stewart C;Li Y;Ma J;Gerbing RB;Alonzo TA;Getz G;Gruber T;Golub T;Stegmaier K;Loh ML
通讯作者：
Loh ML
影响因子：
16.6
作者：
Lipka DB;Witte T;Toth R;Yang J;Wiesenfarth M;Nöllke P;Fischer A;Brocks D;Gu Z;Park J;Strahm B;Wlodarski M;Yoshimi A;Claus R;Lübbert M;Busch H;Boerries M;Hartmann M;Schönung M;Kilik U;Langstein J;Wierzbinska JA;Pabst C;Garg S;Catalá A;De Moerloose B;Dworzak M;Hasle H;Locatelli F;Masetti R;Schmugge M;Smith O;Stary J;Ussowicz M;van den Heuvel-Eibrink MM;Assenov Y;Schlesner M;Niemeyer C;Flotho C;Plass C
通讯作者：
Plass C
影响因子：
10.1
作者：
Niemeyer, Charlotte M.;Loh, Mignon L.;Yoshimi, Ayami
通讯作者：
Yoshimi, Ayami